References
Agostoni PG, De Cesare N, Doria E, Polese A, Tamborini G, et al. Afterload reduction: a comparison of captopril and nifedipine in dilated cardiomyopathy. British Heart Journal 55: 391–399, 1986
Alicandri C, Fariello R, Boni E, Zaninelli A, Muiesan G. Ibopamine vs digoxin in chronic heart failure: a double-blind, crossover study. Journal of Cardiovascular Pharmacology 14 (Suppl. 8): S77–S82, 1989
Arnold SB, Byrd RC, Meist W, Melmon K, Chitlin MD, et al. Long-term digitalis therapy improves left ventricular function in heart failure. New England Journal of Medicine 303: 1443–1448, 1980
Beaune J. Comparison of enalapril versus digoxin for congestive heart failure. American Journal of Cardiology 63: 22D-25D, 1989
Birnbaumer L. Transduction of receptor signal into modulation of effector activity by G proteins: the first 20 years or so. FA-SEB Journal 4: 3178–3188, 1990a
Birnbaumer L. G proteins in signal transduction. Annual Reviews of Pharmacology and Toxicology 30: 675–705, 1990
Bonow RO, Dilsizian V, Rosing DR, Maron BJ, Bacharach SL, et al. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects. Circulation 72: 853–864, 1985
Bristol JA, Evans DB. Agents for the treatment of heart failure Medicinal Research Reviews 3: 259–287, 1983
Bristow MR, Ginsburg W, Minobe W, Cubiciotti RS, Sageman WS, et al. Decreased catecholamine sensitivity and β-adrenergic receptor density in failing human hearts. New England Journal of Medicine 307: 205–211, 1982
Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. Journal of the American Medical Association 259: 539–544, 1988
Cargnelli G, Piovan D, Bova S, Padrini R, Ferrari M. Present and future trends in research and clinical applications of inodilators. Journal of Cardiovascular Pharmacology 14 (Suppl. 8): S124–132, 1989
Charlap S, Lichstein E, Frishman WH. β-adrenergic blocking drugs in the treatment of congestive heart failure. Medical Clinics of North America 73: 372–385, 1989
Cohn JN. Inotropic therapy for heart failure: paradise postponed. New England Journal of Medicine 320: 729–731, 1989
Cohn JN. Mechanisms in heart failure and the role of angiotensin-converting enzyme inhibition. American Journal of Cardiology 66: 2D-6D, 1990
Cohn JN, Archibald DG, Francis GS, Ziesche S, Franciosa JA, et al. Veterans Administration Cooperative Study on vasodilator therapy of heart failure: influence of prerandomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate. Circulation 75: IV–49–54, 1987
Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, et al. Effects of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. New England Journal of Medicine 314: 1429–1435, 1986
Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. New England Journal of Medicine 325: 303–310, 1991
Cohn JN, Rector TS. Prognosis of congestive heart failure and predictors of mortality. American Journal of Cardiology 62: 25A-30A, 1988
Colucci WS, Wright RF. Braunwald E. New positive inotropic agents in the treatment of congestive heart failure: mechanisms of action and recent clinical developments. New England Journal of Medicine 314: 290–299, 1986
CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative North Scandinavian enalapril survival study (CONSENSUS). New England Journal of Medicine 316: 1429–1435, 1987
Cowley AJ, Wynne RD, Stainer K, Fullwood L, Rowley JM, et al. Flosequinan in heart failure: acute haemodynamic and longer term symptomatic effects. British Medical Journal 297: 169–173, 1988
DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, et al. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. New England Journal of Medicine 320: 677–683, 1989
Dobbs SM, Kenyon WL, Dobbs RJ. Maintenance digoxin after an episode of heart failure: placebo-controlled trial in outpatients. British Medical Journal 1: 749–752, 1977
Engelmeier RS, O’Connel JB, Walsh R, Rad N, Scanlon PJ, et al. Improvement in systems and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double blind randomized, placebo-controlled trial. Circulation 72: 536–546, 1985
Evans DB, Weishaar RE, Kaplan HR. Strategy for the discovery and development of positive inotropic agents. Pharmacology and Therapeutics 16: 303–330, 1982
Falotico R, Haertlein BJ, Lakas-Weiss CS, Salata JJ, Tobia AJ. Positive inotropic and hemodynamic properties of flosequinan, a new vasodilator, and a sulfone metabolite. Journal of Cardiovascular Pharmacology 14: 412–418, 1989
Feldman AM, Cates AE, Veazey WB, Hershberger RE, Bristow MR, et al. Increase of the 40,000 mol wt. pertussis toxin substrate (G-protein) in the failing human heart. Journal of Clinical Investigation 82: 189–197, 1988
Ferner GR, Saudners JH, Mendez C. A cellular mechanism for the generation of ventricular arrhythmias by acetylstrophanthidin. Circulation Research 32: 600–609, 1973
Fleg L, Gottlieb SH, Lakatta EG. Is digoxin really important in compensated heart failure? American Journal of Medicine 73: 244–250, 1982
Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow MR. Assessment of the β-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation 74: 1290–1304, 1986
Francis GS, Cohn JN. Heart failure: mechanisms of cardiac and vascular dysfunction and the rationale for pharmacologic intervention. FASEB Journal 4: 3068–3075, 1990
Geltman EM. Mild heart failure: diagnosis and treatment. American Heart Journal 118: 1277–1291, 1989
German and Austrian Xamoterol Study Group. Double-blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure. Lancet 1: 399–493, 1988
Goldberg LI, Rajfer SI. Dopamine receptors: applications in clinical cardiology. Circulation 72: 245–248, 1985
Gradman A, Deedwania P, Cody R, Massie B, Packer M, et al. Predictors of total mortality and sudden death in mild to moderate heart failure. Captopril-Digoxin Study Group. Journal of the American College of Cardiology 14: 564–570, 1989
Greenberg S, Touhey B. Positive inotropy contributes to the hemodynamic mechanism of action of flosequinan (BTS 49465) in the intact dog. Journal of Cardiovascular Pharmacology 15: 900–910, 1990
Guyatt GH, Sullivan MJJ, Fallen EL, Tihal H, Rideout E, et al. A controlled trial of digoxin in congestive heart failure. American Journal of Cardiology 61: 371–375, 1988
Heilbrunn SM, Shah P, Bristow MR, Valentine HA, Ginsburg R, et al. Increased β-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation 79: 483–490, 1989
Hopf R, Kaltenbach M. Management of hypertrophic cardiomyopathy. Annual Review of Medicine 41: 75–83, 1990
Horn EM, Corwin SJ, Steinberg SF, Chow YK, Neuberg GW, et al. Reduced lymphocyte stimulatory guanin nucleotide regulatory protein and β-adrenergic receptors with angiotensin converting enzyme inhibitor therapy. Circulation 78: 1373–1379, 1988
Ikram H, Chan W, Espiner EA, Nicholls MG. Haemodynamic and hormone responses to acute and chronic frusemide therapy in congestive heart failure. Clinical Science 59: 443–449, 1980
Ikram H, Fitzpatrick D. Beta blockade for dilated cardiomyopathy: the evidence against therapeutic benefit. European Heart Journal 4 (Suppl. A): 179–180, 1983
Kelly RA. Cardiac glycosides and congestive heart failure. American Journal of Cardiology 65: 10E-16E 1990
Kessler PD, Packer M. Hemodynamic effects of BTS 49465, a new long-acting systemic vasodilator drug, in patients with severe congestive heart failure. American Heart Journal 113: 137–143, 1987
Kimmelstiel C, Benotti JR. How effective is digitalis in the treatment of congestive heart failure? American Heart Journal 116: 1063–1070, 1988
Kleber FX. Einfluss von Captopril auf die Lebenserwartung bei Patienten mit chronischer Herzinsuffizienz. Herz 12 (Suppl. 1): 38, 1987
Lee DC, Johnson RA, Bingham JB, Leahy M, Dinsmore RE, et al. Heart failure in outpatients: a randomized trial on digoxin versus placebo. New England Journal of Medicine 306: 699–705, 1982
Likoff MJ, Chandler SL, Kay HR. Clinical determinants of mortality in chronic congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. American Journal of Cardiology 59: 634–638, 1987
Longabaugh JP, Vatner DE, Vatner SF, Homey CJ. Decreased stimulatory guanosine triphosphate binding protein in dogs with pressure overload left ventricular failure. Journal of Clinical Investigation 81: 420–424, 1988
Luu M, Stevenson WG, Stevenson LW, Baron K, Waiden J. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation 80: 1675–1680, 1989
Marantz PR, Alderman MH, Tobin JN. Diagnostic heterogeneity in clinical trials for congestive heart failure. Annals of Internal Medicine 109: 55–61, 1988
Massie B, Bourassa M, DiBianco R, Hess M, Konstam M, et al. Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial. Circulation 71: 963–971, 1985
Massie BM, Conway M. Survival of patients with congestive heart failure: past, present and future prospects. Circulation 75: IV–11–19, 1987
McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. New England Journal of Medicine 285: 1441–1446, 1971
Muller JE, Turi ZG, Stone PH, Rude RE, Raabe DS, et al. Digoxin therapy and mortality after myocardial infarction: experience in the MILIS study. New England Journal of Medicine 314: 265–271, 1986
Mulrow CD, Feussner JR, Velez R. Reevaluation of digitalis efficacy: new light on an old leaf. Annals of Internal Medicine 101: 113–117, 1984
Opie LH. Inodilators. Lancet 1: 1336–1339, 1986
Packer M. Prolonging life in patients with congestive heart failure: the next frontier. Circulation 75: IV–1–3, 1987
Packer M, Leier CV. Survival in congestive heart failure during treatment with drugs with positive inotropic actions. Circulation 75: IV–55–63, 1987
Packer M, Medina N, Yushak M. Relation between serum sodium concentration and the hemodynamic and clinical responses to converting enzyme inhibition with captopril in severe heart failure. Journal of the American College of Cardiology 3: 1035–1043, 1984
Parmley WW. An overview of integration of therapy for congestive heart failure. Journal of Cardiovascular Pharmacology 14 (Suppl. 5): S73–S77, 1989
Poole-Wilson PA. Future perspectives in the management of congestive heart failure. American Journal of Cardiology 66: 462–467, 1990
Rector TS, Olivari MT, Levine TB, Francis GS, Cohn JN. Predicting survival for an individual with congestive heart failure using the plasma norepinephrine concentration. American Heart Journal 114: 148–152, 1987
Riegger GAJ, Kochsiek K. Vasopressin, renin and norepinephrine levels before and after captopril administration in patients with congestive heart failure due to idiopathic dilated cardiomyopathy. American Journal of Cardiology 58: 300–303, 1986
Roden DM. Magnesium treatment of ventricular arrhythmias. American Journal of Cardiology 63: 43G-46G, 1989
Rolandi E, Sabino F, Cantoni V, Ghirardi P, Marchetti GV, et al. Long-term therapy of chronic congestive heart failure with ibopamine: a multicenter trial. Journal of Cardiovascular Pharmacology 14 (Suppl. 8): 93–103, 1989
Rüegg JC, Morano I. Calcium-sensitivity modulation of cardiac myofibrillar proteins. Journal of Cardiovascular Pharmacology 14 (Suppl. 3): S11–S14, 1989
Ryan TJ, Bailey KR, McCabe CH, Luk S, Fisher LD, et al. The effects of digitalis on survival in high-risk patients with coronary artery disease: the Coronary Artery Surgery Study (CASS). Circulation 67: 735–742, 1983
Schmitz W, von der Leyen H, Meyer W, Neumann J, Scholz H. Phosphodiesterase inhibition and positive inotropic effects. Journal of Cardiovascular Pharmacology 14: S11–S14, 1989
Schwinger RHG, Böhm M, Erdmann E. Therapie der chronischen Herzinsuffizienz mit β-Rezeptorenblockern? Deutsche Medizinische Wochenschrift 115: 825–831, 1990
Sharpe DN, Murphy J, Coxon R, Hannan SF. Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study. Circulation 70: 271–278, 1984
Smith TW, Butler VP, Haber E, Fozzard H, Marcus FI, et al. Treatment of life threatening digitalis intoxication with digoxin-specific Fab fragments: experience in 26 cases. New England Journal of Medicine 307: 1357–1362, 1982
Smith TW, Haber E. Digoxin intoxication: the relationship of clinical presentation to serum digoxin concentration. Journal of Clinical Investigation 49: 2377–2386, 1970
Smith WM. Epidemiology of congestive heart failure. American Journal of Cardiology 55: 3A-8A, 1985
SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New England Journal of Medicine 325: 293–302, 1991
Stiles GL. Adrenergic receptor responsiveness and congestive heart failure. American Journal of Cardiology 67: 13C-17C, 1991
Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet 1: 1374–1376, 1979
Taggart AJ, Johnston GD, McDevitt DG. Digoxin withdrawal after cardiac failure in patients with sinus rhythm. Journal of Cardiovascular Pharmacology 5: 229–234, 1983
Tischler MD, Smith TW. Digitalis: its current place in the treatment of heart failure. Modern Concepts of Cardiovascular Disease 59: 67–72, 1990
Uretsky BF, Jessup M, Konstam MA, Dec GW, Leier CV, et al. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure: lack of benefit compared with placebo. Circulation 82: 774–780, 1990
Vigholt-Sorensen E, Faergeman O. Ischaemic left ventricular failure: evidence of sustained benefit after 18 months’ treatment with xamoterol. British Heart Journal 64: 186–189, 1990
Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. British Journal 37: 1022–1036, 1975
Williams JF. Evolving concepts in congestive heart failure: Part 1. Modern Concepts of Cardiovascular Disease 59: 43–48, 1990
Williams JF. Evolving concepts in congestive heart failure: Part 2. Modern Concepts of Cardiovascular Diseases 59: 49–53, 1990
Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet 336: 1–6, 1990
Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarctions: an overview of the randomized trials. Progress in Cardiovascular Disease 27: 335–371, 1985
Yusuf S, Wittes J, Bailey K, Furberg C. Digitalis — a new controversy regarding an old drug: the pitfalls of inappropriate methods. Circulation 73: 14–18, 1986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ravens, U., Wehr, M. Treatment of Mild Congestive Heart Failure. Drug-Safety 6, 393–401 (1991). https://doi.org/10.2165/00002018-199106060-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-199106060-00001